Successful Treatment of Myeloid Sarcoma in an Elderly Patient with Myelodysplastic Syndrome with Reduced-Dose Azacitidine.
Journal
Case reports in hematology
ISSN: 2090-6560
Titre abrégé: Case Rep Hematol
Pays: United States
ID NLM: 101576456
Informations de publication
Date de publication:
2021
2021
Historique:
received:
16
11
2020
revised:
06
04
2021
accepted:
13
04
2021
entrez:
12
5
2021
pubmed:
13
5
2021
medline:
13
5
2021
Statut:
epublish
Résumé
Myeloid sarcoma (MS), which involves extramedullary lesions, is classified as a unique subtype of acute myeloid leukemia (AML). At present, no standard treatments for MS have been established. The patient was an 89-year-old man with myelodysplastic syndrome-excess blast-2 (MDS-EB-2) with a 2-year history of intermittent treatment with azacitidine (AZA) during a 4-year history of MDS. He developed painful cutaneous tumors 8 months after the second discontinuation of AZA. They were refractory for antibiotics and topical tacrolimus hydrate. A tumor biopsy was performed, and the histological findings of the tumor lesion showed a proliferation of tumor cells that were positive for myeloperoxidase and CD68 and negative for CD4 and CD123. The patient was diagnosed with MDS-associated MS. MDS-EB-2 quickly progressed to AML with the appearance of peripheral blood blasts and 25% bone marrow blasts. Monotherapy with reduced-dose AZA (37.5 mg/m
Identifiants
pubmed: 33976945
doi: 10.1155/2021/6640597
pmc: PMC8084685
doi:
Types de publication
Case Reports
Langues
eng
Pagination
6640597Informations de copyright
Copyright © 2021 Kazuya Sato et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest in association with the present study.
Références
Lancet Oncol. 2009 Mar;10(3):223-32
pubmed: 19230772
Case Rep Ophthalmol. 2016 Jan 08;7(1):25-9
pubmed: 26889156
Eur J Dermatol. 2015 Nov-Dec;25(6):622-3
pubmed: 26552844
Front Pharmacol. 2018 Nov 13;9:1279
pubmed: 30483125
Ann Hematol. 2018 Aug;97(8):1485-1486
pubmed: 29600420
Leukemia. 2007 Feb;21(2):340-50
pubmed: 17170724
Blood. 2011 Oct 6;118(14):3785-93
pubmed: 21795742
Leuk Lymphoma. 2013 Feb;54(2):411-2
pubmed: 22694794
Clin Lymphoma Myeloma Leuk. 2019 Oct;19(10):603-618
pubmed: 31371220
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Leuk Lymphoma. 2007 Aug;48(8):1628-9
pubmed: 17701595
Ann Hematol. 2017 Mar;96(3):505-506
pubmed: 27817041
Leukemia. 2015 Sep;29(9):1875-81
pubmed: 25943181
Blood. 1997 Mar 15;89(6):2079-88
pubmed: 9058730
Bone Marrow Transplant. 2013 Jul;48(7):994-5
pubmed: 23292243
Medicine (Baltimore). 2017 Sep;96(36):e7975
pubmed: 28885352
Leuk Res. 2010 Sep;34(9):1151-7
pubmed: 20569983
Int J Hematol. 2018 Aug;108(2):121-122
pubmed: 29779081
Hematol Oncol Clin North Am. 2010 Apr;24(2):389-406
pubmed: 20359633
Curr Oncol Rep. 2020 Jun 24;22(7):75
pubmed: 32577912
Blood. 2012 Sep 20;120(12):2454-65
pubmed: 22740453
Oncol Lett. 2020 Feb;19(2):1317-1321
pubmed: 31966063
Blood. 2010 Sep 16;116(11):1908-18
pubmed: 20530795
Blood. 2012 Apr 5;119(14):3361-9
pubmed: 22234690
Turk J Haematol. 2017 Jun 5;34(2):192-193
pubmed: 28183685
Bone Marrow Transplant. 2012 Jul;47(7):1008-9
pubmed: 22080965
Hematology. 2020 Dec;25(1):414-423
pubmed: 33191860